High materiality7/10
ResMed price target lowered to $266 from $290 at KeyBanc
Why it may matterVerify against the original reporting
Lower target but remains well above the current price, implying continued bullish bias.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst target update: RMD price target lowered to $266 from $290; current price $188.63.
- Target cut to $266 from $290; price $188.63.
Key facts
- 01
Target: $266
- 02
Posted price: $188.63
- 03
Analyst firm: KeyBanc
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.